Search Results

You are looking at 1 - 10 of 92 items for :

  • "thyroid cancer" x
  • All content x
Clear All
Open access

Joanna Klubo-Gwiezdzinska, John Costello Jr, Kirk Jensen, Aneeta Patel, Rok Tkavc, Douglas Van Nostrand, Kenneth D Burman, Leonard Wartofsky, and Vasyl Vasko

Introduction Standard treatment of thyroid cancer consists of surgical resection and radioiodine ( 131 I) therapy ( 1 ). Depending on the risk stratification of the individual patient, the primary goal of the application of radioactive iodine

Open access

Chiara Mele, Maria Teresa Samà, Alessandro Angelo Bisoffi, Marina Caputo, Valentina Bullara, Stefania Mai, Gillian Elisabeth Walker, Flavia Prodam, Paolo Marzullo, Gianluca Aimaretti, and Loredana Pagano

Introduction The incidence rates of differentiated thyroid cancer (DTC) have been rising in many countries over the last few decades ( 1 , 2 ) along with a parallel increase in obesity and metabolic disorders ( 3 ). Even if the growing

Open access

Zeming Liu, Di Hu, Yihui Huang, Sichao Chen, Wen Zeng, Ling Zhou, Wei Zhou, Min Wang, Haifeng Feng, Wei Wei, Chao Zhang, Danyang Chen, and Liang Guo

carcinoma. Among pediatric patients, papillary thyroid carcinoma and follicular thyroid cancer account for more than 90% ( 2 ) of all childhood cases. However, medulary thyroid cancer, poorly differentiated tumors and undifferentiated (anaplastic) thyroid

Open access

M L Gild, M Bullock, C K Pon, B G Robinson, and R J Clifton-Bligh

including prostate (9) , non small cell lung cancer (10) , and osteosarcoma (11) . With regard to thyroid cancer, early studies have yielded data that supports the potential clinical utility of targeting HSP90 to treat this disease. 17-AAG has showed an

Open access

Joana Simões-Pereira, Daniel Macedo, and Maria João Bugalho

Introduction Thyroid cancer usually has a favorable prognosis with a reported 10-year survival for differentiated and medullary thyroid carcinoma of approximately 80–95% ( 1 ) and 68–85% ( 2 , 3 ), respectively. Distant metastases occur in a

Open access

Mabel E Bohórquez, Ana P Estrada, Jacob Stultz, Ruta Sahasrabudhe, John Williamson, Paul Lott, Carlos S Duque, Jorge Donado, Gilbert Mateus, Fernando Bolaños, Alejandro Vélez, Magdalena Echeverry, and Luis G Carvajal-Carmona

Introduction Thyroid cancer (TC) is becoming epidemic, growing in incidence both nationally and internationally ( 1 ). Nonmedullary thyroid cancer (NMTC) makes up over 95% of all cases, making it the most common endocrine malignancy ( 2

Open access

Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza, and Navin Niles

). Differentiated thyroid cancers (DTC; both papillary (PTC) and follicular (FTC) histologies), derived from thyroid follicular cells, are the most common subtype, accounting for approximately 90% of all newly diagnosed cases ( 2 ). Standard of care for these

Open access

T Grimmichova, M Haluzik, K Vondra, P Matucha, and M Hill

Introduction Thyroid cancer (TC) is a relatively rare cancer, with an incidence from 1 to 5.3% of all malignancies, but it represents the most common malignancy originating from the endocrine organs. The most common TCs are differentiated

Open access

Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim, and Erik K Alexander

Introduction Well-differentiated thyroid cancer is common, easily identified, and often curable. While the incidence of thyroid cancer has nearly tripled in the past three decades, mortality rates have remained stable (1, 2, 3) . This underscores

Open access

Ashley N Reeb, Andrea Ziegler, and Reigh-Yi Lin

Introduction Follicular thyroid cancer (FTC) is the second most frequently diagnosed thyroid cancer after papillary thyroid cancer (PTC). About 10,000 cases of FTC are diagnosed annually in the United States, comprising about 10–15% of all